2024-10-21
Participating in CPHI Worldwid
Release Time: 2024-09-03
News Source: PharmaCompass
Author: SENOVA—Lucas
Lilly to sell Zepbound vials directly to consumers at 50% discount over Wegovy.
Eli Lilly said it will start selling low starter doses of Zepbound (tirzepatide) for much cheaper through its telehealth platform LillyDirect, launched in January. The 2.5 mg vials of Zepbound will cost just US$ 399, which is a 40 percent discount over the monthly cost of US$ 650 for the pen version. Lilly said the prices represent a 50 percent or more discount compared to rival obesity drugs including Novo’s Wegovy (semaglutide). The drugmaker said the move is part of its efforts to protect the public from compounded versions.
